Stockscreener 앱 받기
10.89
0.00%
0.00
시간 외 거래:
10.67
-0.22
-2.02%
전일 마감가:
$10.89
열려 있는:
$11.16
하루 거래량:
59,626
Relative Volume:
66.00
시가총액:
$168.35M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.00%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$10.89
$11.81
1주일 범위
$10.89
$11.81
52주 변동 폭
$10.89
$11.81
Satellos Bioscience Inc Stock (MSLE) Company Profile
Compare MSLE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MSLE
Satellos Bioscience Inc
|
10.89 | 173.91M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.87 | 121.26B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.28 | 83.04B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
828.24 | 50.22B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.00 | 43.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
348.85 | 39.16B | 4.98B | 69.60M | 525.67M | 0.5198 |
Satellos Bioscience Inc 주식(MSLE)의 최신 뉴스
Satellos Bioscience raises $57.2 million in public offering By Investing.com - Investing.com Nigeria
Satellos Bioscience Completes $57.2 Million Public Offering - marketscreener.com
Satellos Closes US$57.2 Million Public Offering in Canada and the United States - marketscreener.com
Satellos Brief: Closes US$57.2M Public Offer in Canada and United States, Including Exercise of Underwriters' Option to Purchase Additional Shares - marketscreener.com
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares - Business Wire
(MSCL) Equity Market Report (MSCL:CA) - Stock Traders Daily
Satellos prices $50M public offering - MSN
Satellos Raises US$50 Million in Cross-Border Offering as Shares Debut on Nasdaq - TipRanks
Satellos Bioscience prices $50 million public offering - Investing.com
Canadian Investment Regulatory Organization Trading HaltMSCL - marketscreener.com
Satellos announces pricing of US$50 million public offering in Canada and the United States - marketscreener.com
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States - Business Wire
Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Applicati - PharmiWeb.com
Satellos announces launch of public offering in Canada and the United States and filing of application to list on Nasdaq - marketscreener.com
Satellos launches public offering, applies for Nasdaq listing - MSN
Satellos Plans Cross-Border Share Offering and Nasdaq Listing to Fund Muscle Disease Pipeline - TipRanks
Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq - marketscreener.com
(MSCL) Advanced Trading Insights (MSCL:CA) - Stock Traders Daily
(MSCL) Strategic Equity Report (MSCL:CA) - Stock Traders Daily
Satellos appoints Antoinette Paone as chief development officer and head of Regulatory Affairs - marketscreener.com
Satellos appoints Antoinette Paone as chief development officer By Investing.com - Investing.com Australia
Satellos Bioscience Inc. - Menafn.com
Satellos Bioscience Taps Antoinette Paone as Chief Development Officer - Contract Pharma
Satellos Strengthens Executive Bench With Veteran Regulator as Duchenne Program Advances - TipRanks
Satellos Biosciences Brief: Appointing Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs - marketscreener.com
Satellos Bioscience Welcomes New Chief Development Officer - GuruFocus
(MSCL) Technical Pivots with Risk Controls (MSCL:CA) - Stock Traders Daily
Satellos Bioscience Brief: Announcing Share Consolidation in Connection with Proposed Nasdaq Listing - marketscreener.com
Satellos announces share consolidation in connection with proposed Nasdaq listing - marketscreener.com
(MSCL) Advanced Equity Analysis (MSCL:CA) - Stock Traders Daily
(MSCL) Technical Data (MSCL:CA) - Stock Traders Daily
(MSCL) Stock Analysis and Trading Signals (MSCL:CA) - Stock Traders Daily
Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy - BioSpace
Satellos receives FDA clearance for phase 2 Duchenne trial - Investing.com
Satellos Tackles Duchenne ‘As Stem Cell People Solving a Stem Cell Problem’ - Citeline News & Insights
Satellos to Participate in December Investor Conferences - Business Wire
Does DMD start in the womb? New research challenges old beliefs. - Muscular Dystrophy News
Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy - BioSpace
Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors - BioSpace
Oral therapy moves to follow-up after strong data in DMD adults - Muscular Dystrophy News
Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy - BioSpace
Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy - BioSpace
Satellos asks FDA to clear Phase 2 trial of DMD treatment - Muscular Dystrophy News
Satellos to Present SAT-3247 Phase 1 Clinical Data in Late-Breaking Poster Session at the 2025 World Muscle Society Congress - Investing News Network
Doubled Grip Strength: Satellos' Novel DMD Drug Heads to Phase 2 Trial After Promising Adult Results - stocktitan.net
Satellos to Participate in Four September Institutional and Retail Investor Conferences - Investing News Network
Here's Why We're Watching Satellos Bioscience's (TSE:MSCL) Cash Burn Situation - Yahoo Finance
Satellos Bioscience: Promising Novel Treatment For Duchenne Muscular Dystrophy (TSX:MSCL:CA) - Seeking Alpha
Satellos Reports Second Quarter 2025 Results and Highlights Upcoming Clinical Milestones - Investing News Network
Encouraging Results from Phase 1 Trials, Says Satellos Chief Scientific Officer. Now It's On to Phase 2 - Managed Healthcare Executive
DMD treatment SAT-3247 safe in trial, shows early signs of efficacy - Muscular Dystrophy News
Satellos Bioscience Inc (MSLE) 재무 분석
Satellos Bioscience Inc (MSLE)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.10%
7.16%
자본화:
|
볼륨(24시간):